Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

Astellas Pharma Inc.

FiercePharma provides news and information related to the pharmaceutical industry, including topics like vaccines, drug delivery, and manufacturing, self-described as highlighting corporations driving change in healthcare.

FiercePharma

Pharma Now is a monthly B2B magazine that covers trends, technological innovations, and insights in the pharmaceutical and biopharmaceutical sectors. It provides industry news and updates, interviews with leaders, market insights, and regulatory updates.

Metric
Company Name	Astellas Pharma Inc.	FiercePharma	Pharma Now
Symbol	4.50K
MSH ID	COM:ASTELLAS	COM:FIERCEPHARMA	LIVE:PHARMANOW
Market	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Commercial & Professional Services	Consumer Services
Industry	Drug Manufacturers - General	Pharmaceuticals	Pharmaceuticals
Country	JP	US	IN
Stage
Employee Count	14.75K
Website	astellas.com	fiercepharma.com	pharmanow.live
LinkedIn			pharma-now
Founders

Metric
Market Cap	19.84B
Enterprise Value
Monthly Web Traffic	336.73K	484.53K
Web Traffic Growth	0.12	-0.10
Valuation
Raised Capital

Metric
Revenue	10.41B
Revenue (LTM)
Revenue (NTM)
Gross Profit	7.87B
EBITDA	2.18B
Operating Income	1.16B
Net Income	110.61M
EPS	0.06
Diluted EPS	0.06
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.82
Operating Profit Margin	0.07
EBITDA Margin	0.21
Net Profit Margin	0.01
Return on Equity	0.01
Return on Assets	0.00
Return on Capital Employed	0.05

4503

COM:ASTELLAS

Astellas Pharma Inc.

Last Close

1,562.00

25/11 06:45

Market Cap

2.98T

Beta: -

Volume Today

14.54M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	90.19
P/B Ratio	1.87
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.95
EV Multiple	15.46

Metric
Days Sales Outstanding	121.18
Days Payables Outstanding	191.91
Days Inventory Outstanding	292.97
Operating Cycle	412.90
Cash Conversion Cycle	217.88
Asset Turnover	0.46

Metric
Operating Cash Flow	1.18B
Free Cash Flow	641.34M
Cash Flow to Debt	0.25
Operating Cash Flow/Sales	0.14
Free Cash Flow Yield	0.05

Metric
Cash & Equivalents	2.18B
Accounts Receivable	-363.07M
Inventory	1.61B
Goodwill	2.72B
Debt to Capitalization	0.37
Debt to Assets	0.25
Current Ratio	0.96
Quick Ratio	0.74

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	0.18
SG&A to Revenue	0.44